Top Suppliers:I want be here


53-41-8

53-41-8 structure
53-41-8 structure

Name androsterone
Synonyms 3-α-hydroxy-5α-Androstan-17-one
MFCD01317504
Androkinine
5a-Androsterone
Androkinin
Androtine
3alpha-Hydroxy-5alpha-androstan-17-one
Atromide ICI
3-Epihydroxyetioallocholan-17-one
(3a,5a)-3-Hydroxyandrostan-17-one
(3α,5α)-3-Hydroxyandrostan-17-one
(3R,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
3α-hydroxy-5α-androstane-17-one
Androtin
3alpha-Hydroxyetioallocholan-17-one
Androstan-3a-ol-17-one
5alpha-Androsterone
3a-Hydroxyetioallocholan-17-one
5alpha-Androstane-3alpha-ol-17-one
Androsterone
trans-Androsterone
Androstan-17-one, 3-hydroxy-, (3α,5α)-
EINECS 200-173-4
Androsterone, trans-
Atromide
(3α,5α)-3-hydroxy-Androstan-17-one
3a-Hydroxy-5a-androstan-17-one
Description Androsterone is a metabolic product of testosterone and can activate Farnesoid X Receptor (FXR).
Related Catalog
Target

Human Endogenous Metabolite

In Vitro Androsterone activates both the mFXR-LBD and the hFXR-LBD, with Androsterone activating the mFXR-LBD more strongly than the hFXR-LBD. Furthermore, cotransfection studies with gal4-hFXR-LBD and SRC-1/VP16 expression plasmids demonstrate that Androsterone potentiates the interaction of SRC-1 with the hFXR-LBD. Several amino acid changes including H294S, S332V, R351H, and Y361F significantly reduce Androsterone activation[1]. Androsterone (5α, 3α-A) (10 to 100 μM) also inhibits epileptiform discharges in a concentration-dependent fashion in the in vitro slice model[2].
In Vivo Androsterone treatment results in a significant induction of small heterodimer partner (SHP), suggesting Androsterone may activate endogenous FXR[1]. Intraperitoneal injection of Androsterone (5α, 3α-A) protects mice in a dose-dependent fashion from seizures in the following models (ED50, dose in mg/kg protecting 50% of animals): 6 Hz electrical stimulation (29.1), pentylenetetrazol (43.5), pilocarpine (105), 4-AP (215), and maximal electroshock (224)[2].
Cell Assay AML-12 cells are used and cultured in a 1:1 mix of DMEM/Ham’s F12 medium supplemented with 10% fetal bovine serum, 1% insulin-transferrin-selenium mix, 40 ng/mL dexamethasone, 100 U/mL penicillin, and 100 μg/mL streptomycin. For gene regulation studies, AML-12 cells are plated in growth medium at 4×105 cells per well in six-well plates. The following day, treatments including Androsterone or dimethylsulfoxide (DMSO) vehicle are added to the medium. At various times after treatment addition, total RNA is prepared. mRNA levels for individual genes are determined by real-time PCR[1].
Animal Admin Castrated male mice 8 to10 wk of age are fed a casein diet for 2 wk before the start of the study. The mice receive daily sc injections of 0.1 mL 90% corn oil/10% ethanol vehicle or 10 mg/mL Androsterone in vehicle. Animals are killed 2 h after the fifth daily treatment, approximately 4 h after commencement of the light cycle. Total RNA is prepared, and mRNA levels for specific genes are determined by real-time PCR[1].
References

[1]. Wang S, et al. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology. 2006 Sep;147(9):4025-33.

[2]. Kaminski RM, et al. Anticonvulsant activity of androsterone and etiocholanolone. Epilepsia. 2005 Jun;46(6):819-27.

Density 1.1±0.1 g/cm3
Boiling Point 413.1±45.0 °C at 760 mmHg
Melting Point 180-185ºC
Molecular Formula C19H30O2
Molecular Weight 290.440
Flash Point 176.4±21.3 °C
Exact Mass 290.224579
PSA 37.30000
LogP 3.75
Vapour Pressure 0.0±2.2 mmHg at 25°C
Index of Refraction 1.536
Name: Androsterone 97% Material Safety Data Sheet
Synonym: 3_-Hydroxy-5_-Androstan-17-One; Cis-Androsterone
CAS: 53-41-8
Section 1 - Chemical Product MSDS Name:Androsterone 97% Material Safety Data Sheet
Synonym:3_-Hydroxy-5_-Androstan-17-One; Cis-Androsterone

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
53-41-8 Androsterone 97 200-173-4
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
Adverse reproductive effects have been reported in animals.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Hormones and antibiotics room.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 53-41-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Granules
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 181.00 - 184.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: practically insoluble
Specific Gravity/Density:
Molecular Formula: C19H30O2
Molecular Weight: 290.44

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 53-41-8: BV8053000 LD50/LC50:
Not available.
Carcinogenicity:
Androsterone - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 53-41-8: No information available.
Canada
CAS# 53-41-8 is listed on Canada's DSL List.
CAS# 53-41-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 53-41-8 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

CHEMICAL IDENTIFICATION

RTECS NUMBER :
BV8053000
CHEMICAL NAME :
5-alpha-Androstan-17-one, 3-alpha-hydroxy-
CAS REGISTRY NUMBER :
53-41-8
BEILSTEIN REFERENCE NO. :
2217626
LAST UPDATED :
199612
DATA ITEMS CITED :
4
MOLECULAR FORMULA :
C19-H30-O2
MOLECULAR WEIGHT :
290.49

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
8400 ug/kg
SEX/DURATION :
male 21 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct
REFERENCE :
ENDOAO Endocrinology (Baltimore). (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21203) V.1- 1917- Volume(issue)/page/year: 21,313,1937
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
80 mg/kg
SEX/DURATION :
female 13-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
REFERENCE :
ENDOAO Endocrinology (Baltimore). (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21203) V.1- 1917- Volume(issue)/page/year: 99,1490,1976 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3818 No. of Facilities: 53 (estimated) No. of Industries: 2 No. of Occupations: 2 No. of Employees: 767 (estimated) No. of Female Employees: 347 (estimated)
Symbol GHS07 GHS08
GHS07, GHS08
Signal Word Danger
Hazard Statements H315-H319-H334-H335
Precautionary Statements P261-P305 + P351 + P338-P342 + P311
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Faceshields;Gloves
Hazard Codes Xi
Risk Phrases 36/37/38-43
Safety Phrases 22-24/25
RIDADR 2811.0
WGK Germany 3
RTECS BV8053000
Hazard Class 6.1